SCHEMBL27191992

SCHEMBL27191992

COc1cc(-c2cc3[nH]c(=O)n(-c4cncc5cccc(Cl)c45)c(=O)c3s2)c(Cl)cc1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGLN3 Q9H6Z9 3/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ HAVCR2 Q8TDQ0 1/20 0.33
▸ GNRHR P30968 2/20 0.32
▸ MAPT P10636 1/20 0.32
▸ MALT1 Q9UDY8 4/20 0.32
▸ BRD4 O60885 1/20 0.32
▸ BRD2 P25440 1/20 0.32
▸ BRD3 Q15059 1/20 0.32
▸ ERCC5 P28715 1/20 0.32
▸ FEN1 P39748 1/20 0.32
▸ HSD17B10 Q99714 2/20 0.31
▸ HTT P42858 1/20 0.31
▸ PKM P14618 1/20 0.31
▸ PDE7A Q13946 1/20 0.31
▸ NPBWR1 P48145 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27192251 0.95 EGLN3 (0.37) EGLN3ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL27192095 0.94 EGLN3 (0.34) EGLN3ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL27192256 0.89 EGLN3 (0.37) EGLN3ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL30702090 0.89 EGLN3 (0.33) EGLN3ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL27192210 0.89 EGLN3 (0.33) EGLN3ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL27192437 0.87 EGLN3 (0.34) EGLN3ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL27191862 0.86 HAVCR2 (0.35) EGLN3ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL30701973 0.86 HAVCR2 (0.34) EGLN3ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL27191903 0.86 HAVCR2 (0.34) EGLN3ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL27191776 0.85 EGLN3 (0.37) EGLN3ALDH1A1SMN1; SMN2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410183-B2 Sars-cov2 main protease inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 — — US disclosed
EP-4565574-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. (US) 2025-06-11 — — EP disclosed
CN-119731159-A SARS-CoV2 main proteinase inhibitor 吉利德科学公司 2025-03-28 — — CN disclosed
US-20250042915-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2025-02-06 — — US disclosed
US-12091420-B2 SARS-COV2 main protease inhibitors GILEAD SCIENCES, INC. (US) 2024-09-17 — — US disclosed
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2024-07-18 — — US disclosed
US-20240116946-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2024-04-11 — — US disclosed
WO-2024031089-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. (US) 2024-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042915-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE EGLN3 1408/4885ALDH1A1 3259/4885SMN1; SMN2 2647/4885
US-12091420-B2 SARS-COV2 main protease inhibitors ACE2, TMPRSS2, ACE EGLN3 1408/4885ALDH1A1 3259/4885SMN1; SMN2 2647/4885
US-20240116946-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE EGLN3 1408/4885ALDH1A1 3259/4885SMN1; SMN2 2647/4885
US-12410183-B2 Sars-cov2 main protease inhibitors ACE2, TMPRSS2, ACE EGLN3 1408/4885ALDH1A1 3259/4885SMN1; SMN2 2647/4885
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE EGLN3 1408/4885ALDH1A1 3259/4885SMN1; SMN2 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback